Forian accepts $2.17 per share tender as consortium locks 70% stake in going-private exit

Forian Inc. accepted a tender offer at $2.17 per share from a consortium that now holds 70% of the cannabis data analytics provider, setting the stage for a going-private transaction that values the company at roughly $60 million. The offer closed with the buyers crossing the threshold required to proceed with a formal squeeze-out of remaining minority holders under Delaware law.

The tender represented a 32% premium to Forian's thirty-day volume-weighted average price at announcement but landed below the company's twelve-month high of $2.85 reached in March. Forian trades on NASDAQ under ticker FORA and closed its most recent session at $2.14, suggesting the market had already priced in acceptance with minimal arbitrage spread remaining. The company provides prescription monitoring and regulatory data infrastructure to cannabis operators and state agencies across 35 jurisdictions, a vertical that has struggled to command public market multiples despite recurring revenue streams.

The consortium's 70% position clears the statutory threshold for a short-form merger under Delaware General Corporation Law Section 253, allowing the buyers to eliminate remaining shareholders without a separate vote within 90 days of tender settlement. This structure compresses the timeline for delisting and removes the risk of activist interference or competing bids that often surface during prolonged merger agreements. For context, similar going-private transactions in microcap software verticals have moved from tender acceptance to final delisting in 60 to 75 days on average over the past eighteen months.

The move follows a pattern in cannabis-adjacent infrastructure plays where public market liquidity dried up faster than expected. Forian's enterprise value at deal price sits at roughly 1.8 times trailing revenue, a discount to traditional healthcare IT comparables trading at 3.5 times to 5 times revenue but consistent with the valuation compression across cannabis supply-chain technology. The company reported $34 million in revenue for the trailing twelve months ending September, with gross margins above 65%, but faced persistent questions about the durability of state contracts as legalization momentum slowed in key markets including Florida and Ohio.

Allocators with positions in microcap M&A arbitrage should note the narrow spread leaves limited upside from here, but the structure offers a clean read-through for other stranded cannabis tech names trading below book value. The consortium has not disclosed financing sources or board composition, though the 70% stake suggests either a strategic buyer with existing domain expertise or a private equity shop willing to hold through federal rescheduling uncertainty. Worth noting: the IRS's proposed rulemaking on Section 280E relief for cannabis businesses remains open for comment through March, which could shift the economics of data providers serving dispensaries that suddenly gain tax deductibility for software costs.

The tender acceptance triggers a 45-day appraisal rights window for dissenting shareholders under Delaware law, though the thin premium and majority control make litigation upside unlikely absent material disclosure failures. Remaining FORA holders should expect delisting notice within 30 days and final cash settlement by late April. The transaction removes one of the few pure-play cannabis data infrastructure names from public markets, leaving compliance software provider Akerna as the closest remaining comparable, itself trading at 0.9 times revenue after a similar valuation collapse.

Forian's exit arrives as cannabis M&A volume remains subdued in the first quarter, with total deal value across the sector down 48% year-over-year through February according to Viridian Capital Advisors. The consortium's willingness to pay a premium, however thin, signals continued private market appetite for cash-generative infrastructure plays even as cultivators and retailers face balance sheet stress. The $2.17 price floor now establishes a floor valuation for peer companies with similar contract structures, particularly those serving state regulatory bodies rather than direct-to-consumer channels.